201 related articles for article (PubMed ID: 36609960)
1. Apremilast in Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Meta-analysis.
Spencer RK; Elhage KG; Jin JQ; Davis MS; Hakimi M; Bhutani T; Liao W
Dermatol Ther (Heidelb); 2023 Feb; 13(2):437-451. PubMed ID: 36609960
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.
Huang IH; Wu PC; Chiu HY; Huang YH
Am J Clin Dermatol; 2024 May; 25(3):347-358. PubMed ID: 38438782
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Efficacy and Safety of Apremilast and Methotrexate in Patients with Palmoplantar Psoriasis: A Randomized Controlled Trial.
Kt S; Thakur V; Narang T; Dogra S; Handa S
Am J Clin Dermatol; 2021 May; 22(3):415-423. PubMed ID: 33712987
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.
Terui T; Okubo Y; Kobayashi S; Sano S; Morita A; Imafuku S; Tada Y; Abe M; Yaguchi M; Uehara N; Handa T; Tanaka M; Zhang W; Paris M; Murakami M
Am J Clin Dermatol; 2023 Sep; 24(5):837-847. PubMed ID: 37233897
[TBL] [Abstract][Full Text] [Related]
5. Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study.
Okubo Y; Terui T; Kobayashi S; Sano S; Morita A; Imafuku S; Tada Y; Abe M; Yaguchi M; Kimura T; Shimauchi J; Zhang W; Amouzadeh H; Murakami M
Dermatol Ther (Heidelb); 2024 Jun; ():. PubMed ID: 38896381
[TBL] [Abstract][Full Text] [Related]
6. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
[TBL] [Abstract][Full Text] [Related]
7. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
Bissonnette R; Haydey R; Rosoph LA; Lynde CW; Bukhalo M; Fowler JF; Delorme I; Gagné-Henley A; Gooderham M; Poulin Y; Barber K; Jenkin P; Landells I; Pariser DM
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):403-410. PubMed ID: 29055155
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
Sanchez IM; Sorenson E; Levin E; Liao W
Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
[TBL] [Abstract][Full Text] [Related]
10. A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
Wilsmann-Theis D; Kromer C; Gerdes S; Linker C; Magnolo N; Sabat R; Reich K; Mössner R
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2045-2050. PubMed ID: 34077577
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of efficacy and tolerability of apremilast and methotrexate in patients of moderate-to-severe palmoplantar psoriasis: A randomized, parallel, open-label clinical trial.
Wagh M; Mukhi J; Sontakke S; Dhok A; Turankar A; Kalikar M
Indian J Pharmacol; 2023; 55(6):356-362. PubMed ID: 38174531
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of anti-interleukin-17A biological agents for palmoplantar psoriasis and palmoplantar pustulosis: A network meta-analysis.
Xia R; Diao Z; Chen D; Wang Y; Zhou C; Gao Y; Yin Z
Int Immunopharmacol; 2024 Mar; 130():111716. PubMed ID: 38417367
[TBL] [Abstract][Full Text] [Related]
13. Interventions for chronic palmoplantar pustulosis.
Obeid G; Do G; Kirby L; Hughes C; Sbidian E; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011628. PubMed ID: 31958161
[TBL] [Abstract][Full Text] [Related]
14. Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study.
Burden AD; Bissonnette R; Navarini AA; Murakami M; Morita A; Haeufel T; Ye B; Baehner F; Terui T
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2279-2297. PubMed ID: 37731086
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate monotherapy versus methotrexate and apremilast combination therapy in the treatment of palmoplantar psoriasis: A prospective, randomised, assessor-blinded, comparative study.
Hassanandani T; Panda M; Jena AK; Raj C
Indian J Dermatol Venereol Leprol; 2023; 89(2):213-220. PubMed ID: 35841363
[TBL] [Abstract][Full Text] [Related]
16. Immediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study.
Kato N; Takama H; Ando Y; Yanagishita T; Ohshima Y; Ohashi W; Akiyama M; Watanabe D
Int J Dermatol; 2021 May; 60(5):570-578. PubMed ID: 33454961
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
Armstrong AW; Betts KA; Sundaram M; Thomason D; Signorovitch JE
J Am Acad Dermatol; 2016 Oct; 75(4):740-746. PubMed ID: 27476973
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis.
Bissonnette R; Maari C; Tsianakas A; Reid D; McCutchan S; Baumgartner S; Mackay J; Bhakta N
Dermatol Ther (Heidelb); 2021 Dec; 11(6):2179-2193. PubMed ID: 34716902
[TBL] [Abstract][Full Text] [Related]
19. Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study.
Reich K; Graff O; Mehta N
Br J Dermatol; 2016 Jun; 174(6):1277-81. PubMed ID: 26800106
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
